دورية أكاديمية
Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma
العنوان: | Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma |
---|---|
المؤلفون: | Annemans, Lieven, Caekelbergh, Karin, Roelandts, Rik, Boonen, Hugo, Leys, Christophe, Nikkels, Arjen, van Den Haute, V., van Quickenborne, L., Verhaeghe, Evelien, Leroy, Bernard |
المصدر: | European Journal of Dermatology, 18 (2008-09) |
بيانات النشر: | John Libbey Eurotext, 2008. |
سنة النشر: | 2008 |
مصطلحات موضوعية: | actinic keratosis, basal cell carcinoma, methyl aminolevulinate, photodynamic therapy, pharmacoeconomics, MAL PDT, kératose actinique, thérapie photodynamique, Human health sciences, Dermatology, Sciences de la santé humaine, Dermatologie |
الوصف: | Photodynamic therapy with methyl aminolevulinate (MAL-PDT) is a non-invasive therapy for superficial and nodular basal cell carcinoma (BCC). We performed an open-label trial to evaluate efficacy, safety, tolerability and cosmetic outcome of MAL-PDT in selected patients with superficial and nodular BCCs. Ninety-four superficial and 24 nodular BCCs in 69 patients were treated with 2 to 8 MAL-PDT sessions. Efficacy, safety, tolerability and cosmetic outcome were evaluated at months 1, 3, 6 and 12 after the last MAL-PDT treatment and then every 3 months. One patient discontinued the study for reasons unrelated to study procedures. Complete clinical regression was detected in 84/94 (89.4%) superficial BCCs, and 12/23 (52.2%) nodular BCCs one month after 2 MAL-PDT sessions. No further clinical improvement was observed in either superficial or nodular BCCs with treatment continuation up to a maximum of 8 MAL-PDT sessions. Adverse effects were limited to mild local skin reactions, and cosmetic outcome was rated as excellent or good. Recurrence was observed in 2/84 (2.4%) successfully treated superficial BCCs at 6 and 12 months after treatment discontinuation. Based on the efficacy, tolerability, cosmetic outcome and recurrence rate, our results support the use of MAL-PDT for treatment of superficial BCC and for selected cases of nodular BCC. |
نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501 article |
اللغة: | English |
DOI: | 10.1684/ejd.2008.0469 |
URL الوصول: | https://orbi.uliege.be/handle/2268/7181 |
حقوق: | restricted access http://purl.org/coar/access_right/c_16ec info:eu-repo/semantics/restrictedAccess |
رقم الأكسشن: | edsorb.7181 |
قاعدة البيانات: | ORBi |
DOI: | 10.1684/ejd.2008.0469 |
---|